Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eric Jacobsen, MD
- Target Recruit Count
- 24
- Registration Number
- NCT06692452
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 215
- Registration Number
- NCT06679829
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Twice-per-weekSelinexor, 2 Days Melphalan
- Conditions
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Target Recruit Count
- 126
- Registration Number
- NCT06613035
- Locations
- 🇨🇳
Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China
🇨🇳Hebei Medical University Second Hospital, Shijiazhuang, hebeisheng, China
🇨🇳The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan, Shandong, China
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT06523699
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 28
- Registration Number
- NCT06377540
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- Biological: Actinium Ac 225-DOTA-DaratumumabProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DaratumumabProcedure: EchocardiographyDrug: FludarabineProcedure: Hematopoietic Cell TransplantationBiological: Indium In 111-DOTA-DaratumumabDrug: MelphalanProcedure: Multigated Acquisition ScanProcedure: Radionuclide ImagingProcedure: Single Photon Emission Computed TomographyDrug: SirolimusDrug: TacrolimusRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06287944
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06207799
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Dual-Energy Computed TomographyProcedure: EchocardiographyDrug: FludarabineProcedure: Magnetic Resonance ImagingDrug: MelphalanProcedure: Multigated Acquisition ScanBiological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201Drug: TacrolimusDrug: ThiotepaRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT06195891
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Conditions
- Interventions
- Drug: Rabbit Anti thymocyte globulinDrug: PlerixaforBiological: Granulocyte Colony-Stimulating FactorDrug: BusulfanDrug: FludarabineDrug: ThiotepaDrug: MelphalanBiological: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graftBiological: memory-like natural killer cellsBiological: IL-2Device: CliniMACS
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT06158828
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.